Events

Daiichi Sankyo is honored to be a Platinum sponsor of LabCentral, a top-tier shared laboratory space in Cambridge, Massachusetts, designed to serve as a launchpad for life science and biotech startups. This year, Daiichi Sankyo will award a Golden Ticket to support and celebrate innovative life-science companies. The recipient of the Golden Ticket will receive a $50,000 credit towards space and services at LabCentral’s flagship site at 700 Main Street in Cambridge, for use within a 13-month period. Additionally, Daiichi Sankyo will offer access to its team of skilled experts, who can provide guidance and feedback to early-stage companies.

Daiichi Sankyo is thrilled to announce the opening of applications for the 2025 Daiichi Sankyo Golden Ticket, inviting startups that are developing innovative technologies and therapeutics in the following areas:

• Modality & Technology: RNA targeting therapeutics, Drug delivery technology to specific organs & cells, Proximity inducing modalities, Novel cell engineering technologies 
• Oncology: Novel tumor-specific therapeutic modalities with unique approach or mechanism, and unique methods for discovering tumor-specific binders
• Specialty Medicine: Novel research for identifying disease-relevant targets using patient tissue samples in central nervous system, cardiovascular, and ophthalmology. Novel in vitro and in vivo models that recapitulate human pathological mechanisms/conditions 

Novel medical device, diagnostics and modality manufacturing are out of scope in 2025 Daiichi Sankyo Golden Ticket. To learn more about Daiichi Sankyo’s strategic areas of interest, please visit our website here.

How to Apply:

To apply, please send a non-confidential pitch deck (up to 20 pages), as a PDF, showcasing your innovative approach to advancing therapies for patients with high unmet needs to: GoldenTickets2025@daiichisankyo.com. All submissions will be reviewed. Semi-finalists will be invited to a pitch event at LabCentral in Cambridge, MA, where the Golden Ticket winners will be announced!

Timeline:

• Application submission opens: January 16, 2025
• Application deadline: February 28, 2025
• Golden Ticket semi-finalists notified: March 28, 2025
• Daiichi Sankyo Golden Ticket pitch event and announcement of finalist: May 1, 2025

Disclosures:

The winner of the Golden Ticket will receive a $50,000 credit towards space and services at LabCentral’s site at 700 Main Street in Cambridge, MA, for use within a 13-month period from the date the winner is offered available lab space. Additional terms and conditions apply, as determined by Daiichi Sankyo and LabCentral. Please visit https://www.labcentral.org/about/golden-tickets to learn more about the process and criteria. All submissions will be reviewed. The recipient will not receive any cash consideration. Those seeking access to, and discussions with, Daiichi Sankyo employees for guidance or feedback may need to sign appropriate confidentiality agreements, at Daiichi Sankyo’s discretion. For any questions, please contact at GoldenTickets2025@daiichisankyo.com.

Daiichi Sankyo:

Daiichi Sankyo Inc is an innovative global healthcare company contributing to the sustainable development of society that discovers, develops and delivers new standards of care to enrich the quality of life around the world. With more than 120 years of experience, Daiichi Sankyo leverages its world-class science and technology to create new modalities and innovative medicines for people with cancer, cardiovascular and other diseases with high unmet medical need. For more information, please visit www.daiichisankyo.com.